Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346135 · ClinicalTrials.gov registry record · Phase 2
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT03346135 is a Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 31 participants, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03346135, a Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
Conditions Studied
Interventions
- DRUG Melphalan
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Daratumumab
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Study Locations (2)
California
- City of Hope Medical Center - Duarte
Tennessee
- Sarah Cannon Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346135
The ClinicalTrials.gov registry entry for NCT03346135 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT03346135 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03346135 about?
NCT03346135 is a clinical study titled "Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma". This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
What is the current status of trial NCT03346135?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-07-17. Estimated completion is 2026-07-01.
What conditions does trial NCT03346135 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Secondary Amyloidosis.
What interventions are being tested in trial NCT03346135?
The interventions under investigation include: Melphalan (DRUG), Laboratory Biomarker Analysis (OTHER), Daratumumab (BIOLOGICAL), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03346135?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03346135 being conducted?
This trial has 2 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenalidomide Maintenance in Plasma Cell Myeloma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.